🍄 Course: How To Grow Mushrooms is open!
Let's Shroom.

Editorial Process

Editorial Process

We’re at a pivotal moment in psychedelic history. Millions of people, who have read about the rigorous, double-blind clinical trials investigating psilocybin and other compounds for mental health, are interested in learning more. And yet, there remain few trusted, accessible resources for people to learn about psychedelics. That’s why we started DoubleBlind. 

DoubleBlind has a joint column on Rolling Stone, where we report on the latest developments in the worlds of psychedelic drug development and policy. We’ve been invited to speak at dozens conferences on the psychedelic movement, including PsyTech, The Mt. Tam Psilocybin Summit, Horizons Convention, and SXSW. We’ve also been featured in and interviewed by numerous publications as experts, including Forbes, Bustle, Business Insider, and VICE.

About Our Contributors

DoubleBlind is devoted to upholding the most rigorous journalistic standards. All data and research cited are fact-checked for rigor and accuracy. We give the full picture, including information on harm reduction and potential risks. All of our articles and webinars feature leading, qualified experts such as Dr. Rick Strassman, associate clinical professor of psychiatry at the University of New Mexico School of Medicine; Dr. James Fadiman, a psychedelic pioneer who has been doing research in the field for more than five decades; mycologist Paul Stamets, author of five mycology books most known for his popular TED talk; Rick Doblin, Ph.D., the founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies; Dr. Jeffrey Becker, a UCLA-trained ketamine researcher and Chief Medical Officer at Bexson Biomedical, among dozens of other scientists and therapists at prominent institutions like Johns Hopkins, New York University, Imperial College London, and beyond. 

All of DoubleBlind’s regular contributors are highly trained journalists with extensive experience covering psychedelics, cannabis, and plant medicines for news outlets including The New York Times, VICE, Rolling Stone, The Guardian, Vanity Fair, and beyond.

It is important to us that when you get information from our site, you know that you can trust it. And we are always available to answer any follow-up questions you may have. You can contact us at: [email protected]

If you’re looking for peer support during or after a psychedelic experience, contact Fireside Project by calling or texting 6-2FIRESIDE. If you or a loved one is struggling with substance use, contact the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 1-800-662-4357 for support.
We have a small favor to ask. Last year, more than five million readers like you visited DoubleBlind’s website. Many of them are suffering and simply seeking trusted information on how to use psychedelics to heal.

We started DoubleBlind two years ago at a time when even the largest magazines and media companies were cutting staff and going out of business. At the time we made a commitment: we will never have a paywall, we will never rely on advertisers we don’t believe in to fund our reporting, and we will always be accessible via email and social media to support people for free on their journeys with plant medicines.

To help us do this, if you feel called and can afford it, we ask you to consider becoming a monthly member and supporting our work. In exchange, you'll receive a subscription to our print magazine, monthly calls with leading psychedelic experts, access to our psychedelic community, and much more.